MiNDERA Corporation
Mindera Health is a US precision medicine company that commercializes Mind.Px, a dermal biomarker patch-based molecular test predicting biologic drug response in moderate-to-severe plaque psoriasis patients, serving dermatologists, payers, PBMs, and government health programs.
- Company typePrivate
- Founded2014
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MiNDERA Corporation does
Mindera Health (legal entity MiNDERA Corporation) is a US-based precision medicine company commercializing Mind.Px, a molecular diagnostic that prospectively predicts individual patient response to biologic drug classes (TNF-alpha, IL-17, IL-23 inhibitors) used to treat moderate-to-severe plaque psoriasis. The proprietary Dermal Intelligence platform combines a minimally invasive, penny-sized dermal biomarker patch that extracts RNA transcripts from skin in roughly five minutes with next-generation sequencing and machine-learning classifiers trained on transcriptomic data from purpose-built clinical cohorts (242-patient STAMP, 205-patient randomized MATCH utility study). Reporting a >91% positive predictive value, 14-day turnaround, and demonstrated annual cost-savings range of $5,138 to $13,141 per patient when clinicians follow the test result, Mind.Px is positioned as a tool to replace the trial-and-error prescribing cycle behind the ~52% average biologic response rate.
The company operates a CAP-accredited, CLIA-certified, ISO 13485:2016-certified diagnostic laboratory in Vista, California, where specimens submitted via test requisition forms from dermatology practices are processed. Revenue is generated almost entirely through laboratory diagnostic testing services billed to insurance payers, Medicare/Medi-Cal, self-funded employers, PBM partners (WellDyne, Liviniti), and government contracts including a 5-year GSA award serving the VA/DOD system and Medi-Cal provider credentialling. The commercial model is enterprise field sales led by a dedicated sales function (VP of Sales, Managed Markets VP, Chief Commercial Officer) layered with network-provider and channel agreements (MultiPlan, Contigo Health, MediNcrease, Occum Health) and employer/payer coverage collaborations (Highmark coverage-with-evidence project). As of the April 2026 SEC Form D filing the company disclosed no revenue, indicating the business remains in pre-revenue commercial buildout despite product availability.
MiNDERA Corporation firmographics
Firmographics- Name
- MiNDERA Corporation
- Legal name
- Mindera Corporation
- Website
- https://minderahealth.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mindera Health is a US precision medicine company that commercializes Mind.Px, a dermal biomarker patch-based molecular test predicting biologic drug response in moderate-to-severe plaque psoriasis patients, serving dermatologists, payers, PBMs, and government health programs.
- Ownership category
- akta.pro rank
MiNDERA Corporation industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)
- akta.pro secondary industries
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where MiNDERA Corporation is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
MiNDERA Corporation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Diagnostic Testing Services: Mind.Px precision medicine test performed in company's CAP accredited, CLIA certified facility in Vista, CA. Test results delivered to ordering physicians within 14 days. Revenue generated through laboratory testing services billed to insurance payers, Medicare/Medi-Cal, and self-funded employers.
- Payer/Reimbursement Contracts: Revenue from contracted relationships with insurance companies, pharmacy benefit managers, and provider networks. Includes coverage with evidence projects, network provider agreements, and government contracts (GSA, VA/DOD facilities, Medi-Cal).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance-based testing with financial assistance available |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
MiNDERA Corporation product offering
Product offeringCore offering
Mindera Health provides Mind.Px, a laboratory-developed molecular diagnostic test that uses a proprietary dermal biomarker patch to extract RNA from psoriatic skin lesions, then applies next-generation sequencing and machine-learning classifiers to prospectively predict individual patient response to biologic drug classes (TNFα, IL-17, IL-23 inhibitors). The test is performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016-certified laboratory in Vista, California, with reports delivered to ordering physicians within 14 days and reimbursed via insurance, Medicare/Medicaid, and self-funded employer channels.
Product overview
Mindera Health operates as a precision medicine company offering a unified platform approach to digital skin analytics. The flagship product is Mind.Px™, a predictive diagnostic test for psoriasis biologic therapy selection, powered by the Dermal Intelligence™ Platform which uses a proprietary dermal biomarker patch for RNA extraction and machine learning analysis. Supporting products include SkinAtlas™ (the molecular data repository) and Subtilitas (a translational research platform). The company commercializes Mind.Px directly to healthcare providers and payers, with financial assistance programs like Mindera Assist available for patients.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- >91% positive predictive value in predicting biologic drug response
- +5 more outcomes
Companies that use MiNDERA Corporation
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
MiNDERA Corporation technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
MiNDERA Corporation partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship and core.
- Mountaineer BiosciencesflagshipLaunched Subtilitas precision translational medicine platform for dermatology and immunology. Integrates Mindera Health's non-invasive skin transcriptomics and data science tools with Mountaineer Biosciences' translational and clinical expertise. Platform enables objective, biology-driven insights for patient stratification, biomarker discovery, and clinical development. Available for partnership with biopharmaceutical companies, academic investigators, and CROs.
- MultiPlancoreNetwork provider agreement for Mindera's Vista, CA laboratory. Mind.Px available to PHCS and MultiPlan Networks health plan members. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers.
- National Psoriasis FoundationcoreStrategic partnership to improve psoriasis patient outcomes and raise awareness of precision medicine. NPF serves more than 4 million people annually with resources, tools, and information. Partnership supports NPF Care Path and helps patients and doctors make more efficient and accurate treatment decisions.
- Medi-CalcoreMedi-Cal provider credentialling enables Mind.Px access for over 15 million Medi-Cal beneficiaries in California. State Medicaid program serves one in three Californians including nearly four in ten children, one in five nonelderly adults, and two million seniors and people with disabilities.
- Liviniti (formerly Southern Scripts)coreInnovative Pharmacy Benefit Manager partnership for psoriasis patient management pilot program. Liviniti serves self-funded employers with pass-through pricing and transparent business model. Collaboration utilizes Mind.Px to improve clinical outcomes while reducing biologic drug costs.
- Occum HealthcoreCommercial agreement making Mind.Px available to Occum Health's more than 500 self-insured clients and key strategic partners. Healthcare solutions company focused on delivering savings and improved benefits to self-insured employers.
- Contigo Health ConfigureNetcoreProvider network contract making Mind.Px available to Contigo Health ConfigureNet clients and their health plan members. Contigo Health is a health benefits platform leading direct-to-employer and direct-to-provider relationships with nationwide provider access.
- General Services Administration (GSA)core5-year GSA contract enabling access to Mind.Px for over 9.6 million veterans, active duty, retirees and their families served by VA Health System and Department of Defense Medical Treatment Facilities.
- MediNcrease Health PlanscoreNational provider network contract making Mind.Px available to more than 15 million lives served by MediNcrease clients and payers. National provider network and provider advocacy firm servicing commercial health, workers' compensation, and auto medical markets.
- Highmark Inc.coreCoverage with evidence project evaluating Mind.Px's impact on physician prescribing behavior and net savings for Pennsylvania, West Virginia and Delaware health plans. CEO of Diversified Businesses Deborah L. Rice-Johnson serves on Mindera Health Board.
- WellDynecoreDefinitive agreement with innovative PBM to improve management of moderate-to-severe psoriasis patients. WellDyne has partnered with more than 2,000 clients managing more than 3 million plan members. Partnership leverages Mind.Px for specialty drug optimization.
Scale indicators19 records
Recent moves7 records
Expansion highlights6 records
MiNDERA Corporation competitors and assessment
Company assessmentDirect peers
- DermTech: Commercial-stage molecular dermatology diagnostics company using non-invasive skin sampling (tape stripping) to detect genomic markers for skin cancer and inflammatory skin conditions. Direct peer to Mindera given shared approach of non-invasive dermal sampling + RNA/molecular analysis for dermatology therapeutic decision-making.
- Castle Biosciences: Molecular diagnostics company with dermatology-focused tests (e.g., DecisionDx-Melanoma, DecisionDx-SCC) that use genomic profiling to guide treatment decisions. Highly relevant peer because of dermatology focus, specialty-Dx business model, and CLIA/CAP certified laboratory operations.
- Exagen: Specialty diagnostics company focused on autoimmune and rheumatic diseases (SLE, RA) with proprietary blood-based biomarker tests used to guide therapy selection. Highly comparable given the CEO overlap (Ron Rocca led Exagen), autoimmune/dermatology adjacency, and precision-medicine payer business model.
Broad incumbents
- Veracyte: Established specialty molecular diagnostics company offering RNA-based genomic tests across oncology and other specialties. Comparable business model of CLIA/CAP-certified specialty lab, payer coverage build-out, and AI/ML-driven decision-support tests for therapy selection.
- Guardant Health: Liquid-biopsy molecular diagnostics company with NGS-based tests for oncology therapy selection and monitoring. Comparable as a multiomic, NGS + ML-driven specialty Dx selling to providers and payers with significant reimbursement and coverage-with-evidence focus.
- Exact Sciences: Large molecular diagnostics company (Cologuard, Oncotype DX, TheraPrint) with extensive payer infrastructure and lab operations. Comparable as a specialty Dx scaling via evidence-based payer coverage and primary/secondary care provider ordering workflows.
- NeoGenomics: Oncology-focused clinical laboratory and molecular diagnostics services company with CLIA-certified labs and broad payer contracts. Comparable as a multiomic specialty Dx with similar cost-of-goods economics and oncology/therapy-selection positioning.
- Natera: Molecular diagnostics company with cell-free DNA and RNA-based specialty tests (oncology, transplant, women's health). Comparable as a multiomic specialty Dx with established payer coverage strategy and recurring test revenue model.
Emerging players
- Tempus AI: AI-powered precision medicine company combining molecular profiling and clinical data for therapy selection and clinical trial enrollment. Comparable because of AI/ML biomarker analytics, pharma/CRO research services, and predictive test positioning.
- SkylineDx: Molecular diagnostics company developing biomarker-based tests for therapy selection, primarily in oncology and inflammatory diseases. Comparable as a translational biomarker Dx that validates transcriptomic signatures to inform therapeutic choice via lab-developed tests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
MiNDERA Corporation social profiles
Digital presenceMiNDERA Corporation compliance and trust
Trust signalCompliance4 records
MiNDERA Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiNDERA Corporation leadership team
Management profileNumber of profiles
Profiles6 records
MiNDERA Corporation funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiNDERA Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiNDERA Corporation
What does MiNDERA Corporation do?
Mindera Health provides Mind.Px, a laboratory-developed molecular diagnostic test that uses a proprietary dermal biomarker patch to extract RNA from psoriatic skin lesions, then applies next-generation sequencing and machine-learning classifiers to prospectively predict individual patient response to biologic drug classes (TNFα, IL-17, IL-23 inhibitors). The test is performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016-certified laboratory in Vista, California, with reports delivered to ordering physicians within 14 days and reimbursed via insurance, Medicare/Medicaid, and self-funded employer channels.
Is MiNDERA Corporation a public or private company?
MiNDERA Corporation is a private company. It is classified as venture growth investor backed and is currently operating.
When was MiNDERA Corporation founded?
MiNDERA Corporation was founded in 2014. It employs 11 to 50 people.
Where is MiNDERA Corporation based?
MiNDERA Corporation is headquartered in South San Francisco, United States, in the North America region.
How does MiNDERA Corporation make money?
Two revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are payer/Reimbursement Contracts.
Who are MiNDERA Corporation's main competitors?
Direct peers on record are DermTech, Castle Biosciences and Exagen. Broad incumbents are Veracyte, Guardant Health, Exact Sciences, NeoGenomics and Natera. Emerging players are Tempus AI and SkylineDx.
Does MiNDERA Corporation have an API?
No public API is recorded for MiNDERA Corporation.
What industry is MiNDERA Corporation in?
MiNDERA Corporation's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays, with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 621511 and its SIC code is 8071.